Literature DB >> 27868287

Development of a nomogram for the prediction of pathological complete response after neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma.

Yin-Kai Chao1, Hsien-Kun Chang2, Chen-Kan Tseng3, Yun-Hen Liu1, Yu-Wen Wen4.   

Abstract

Nomograms incorporating multiple prognostic factors are useful for individualized estimation of survival in cancer patients. However, nomograms for the prediction of pathological complete response (pCR) after neoadjuvant chemoradiotherapy (nCRT) in patients with esophageal cancer are scarce. Here, we describe the development of a nomogram for predicting pCR after nCRT in patients with esophageal squamous cell carcinoma (ESCC). We retrospectively reviewed the records of 392 ESCC patients who underwent nCRT followed by esophagectomy. Seventy percent of the participants (n = 274) were randomly assigned to a training cohort, whereas the remaining 30% were included in a validation cohort (n = 118). Data from the training cohort were subjected to multivariate logistic regression analyses for selecting variables to be included in the nomogram. The performance of the resulting nomogram was internally and externally validated by calculating the bias-corrected concordance statistic (c-statistic) and the area under the receiver operating characteristics curve (AUROC) in the training and validation cohorts, respectively. After surgery, 25.77% of the study patients achieved pCR. The following variables were included in the nomogram: (i) age, (ii) pretreatment tumor length, (iii) history of head and neck cancer, (iv) post-nCRT albumin levels, and (v) post-nCRT endoscopic findings coupled with endoscopic biopsy results. The bias-corrected c-statistic and AUROC of the internal and external validation sets were 0.77 and 0.747, respectively. Our nomogram showed a good performance for predicting pCR after nCRT in ESCC patients.
© 2016 International Society for Diseases of the Esophagus.

Entities:  

Keywords:  esophageal cancer; neoadjuvant chemoradiotherapy; nomogram; pathological complete response; squamous cell carcinoma

Mesh:

Year:  2017        PMID: 27868287     DOI: 10.1111/dote.12519

Source DB:  PubMed          Journal:  Dis Esophagus        ISSN: 1120-8694            Impact factor:   3.429


  4 in total

1.  Pathological complete response after neoadjuvant treatment determines survival in esophageal squamous cell carcinoma patients (NEOCRTEC5010).

Authors:  Jianfei Shen; Min Kong; Hong Yang; Ke Jin; Yuping Chen; Wentao Fang; Baofu Chen; Chengchu Zhu; Zhentao Yu; Weimin Mao; Jiaqing Xiang; Yongtao Han; Zhijian Chen; Haihua Yang; Jiaming Wang; Qingsong Pang; Xiao Zheng; Huanjun Yang; Tao Li; Xu Zhang; Qun Li; Geng Wang; Teng Mao; Xufeng Guo; Ting Lin; Mengzhong Liu; Dehua Ma; Minhua Ye; Chunguo Wang; Zheng Wang; Alessandro Brunelli; Robert J Cerfolio; Xavier Benoit D'Journo; Hiran C Fernando; Florian Lordick; Jianhua Fu
Journal:  Ann Transl Med       Date:  2021-10

2.  Second primary malignancy in patients with esophageal adenocarcinoma and squamous cell carcinoma.

Authors:  Guoqing Zhang; Bin Wu; Xiaofei Wang; Jindong Li
Journal:  Medicine (Baltimore)       Date:  2019-09       Impact factor: 1.817

3.  Prediction of Pathologic Response to Neoadjuvant Chemoradiotherapy in Patients with Esophageal Squamous Cell Carcinoma Incorporating Hematological Biomarkers.

Authors:  Yingjia Wu; Jinbin Chen; Lei Zhao; Qiaoqiao Li; Jinhan Zhu; Hong Yang; Suping Guo; Mian Xi
Journal:  Cancer Res Treat       Date:  2020-09-04       Impact factor: 4.679

4.  A reliable nomogram model for predicting esophageal stricture after endoscopic submucosal dissection.

Authors:  Guodong Yang; Zhao Mu; Ke Pu; Yulin Chen; Luoyao Zhang; Haiyue Zhou; Peng Luo; Xiaoying Zhang
Journal:  Medicine (Baltimore)       Date:  2022-02-04       Impact factor: 1.889

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.